Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

Immunic (IMUX) announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, demonstrated a ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Dr. Corey L. Hartman tells ESSENCE how this prescription can have long-term effects not just the body—but also on our skin.